Table 2.
Associations of ferritin levels in CHC patients at baseline.
| Baseline factors | Univariate analyses | Multivariate analyses | ||
|---|---|---|---|---|
| 95% CI of OR (OR) | p values | 95% CI of OR (OR) | p values | |
| Male, yes | 98.3 ~ 225.5 (161.9) | < 0.001 | 2.935 ~ 130.3 (66.6) | 0.04 |
| Age (years) | 0.667 ~ 5.741 (3.20) | 0.013 | − 4.366 ~ 1.196 (− 1.58) | 0.264 |
| BMI (kg/m2) | − 0.348 ~ 12.89 (4.71) | 0.26 | ||
| HCV genotype | − 27.77 ~ 18.99 (− 4.39) | 0.712 | ||
| Log HCV RNA (logIU/mL) | − 60.1 ~ 7.4 (− 26.3) | 0.126 | ||
| ALT (U/L) | 1.457 ~ 2.055 (1.756) | < 0.001 | 0.841 ~ 1.381 (1.111) | < 0.001 |
| eGFR (mL/min/1.73 m2) | − 1.69 ~ − 1.007 (− 0.849) | 0.048 | − 1.97 ~ − 0.162 (− 1.066) | 0.021 |
| TG (mg/dL) | 1.452 ~ 2.657 (2.055) | < 0.001 | 0.793 ~ 1.904 (1.349) | < 0.001 |
| TC (mg/dL) | − 0.9 ~ 1.032 (0.066) | 0.893 | ||
| HOMA-IR | 2.054 ~ 15.057 (8.655) | 0.01 | 0.806 ~ 12.073 (6.439) | 0.025 |
| Uric acid (mg/dL) | 33.87 ~ 76.18 (55.0) | < 0.001 | − 14.864 ~ 23.74 (4.438) | 0.652 |
| Fe/TIBC (%) | 1428 ~ 1722 (1575) | < 0.001 | 1252 ~ 1565 (1409) | < 0.001 |
| Hb (g/dL) | 6.91 ~ 41.69 (24.3) | 0.006 | − 50.21 ~ − 13.5 (− 31.86) | 0.001 |
| NLR | − 23.8 ~ 43.4 (9.8) | 0.567 | ||
| Platelet (103/μL) | − 1.557 ~ − 0.588 (− 1.07) | < 0.001 | − 3.46 ~ − 0.875 (0.265) | 0.395 |
| Steatosis, yes | − 8.2 ~ 118.5 (55.1) | 0.188 | ||
| Liver cirrhosis, yes | − 107.7 ~ 52.4 (− 26.6) | 0.519 | ||
| Fibrosis-4 index | 16.4 ~ 34.8 (25.4) | < 0.001 | − 3.20 ~ 20.42 (8.606) | 0.153 |
|
IFNL3-rs12979860 CC genotype, yes |
− 227.7 ~ − 34.7 (− 131.2) | 0.008 | − 181.9 ~ − 31.46 (− 106.2) | 0.005 |
CHC chronic hepatitis C virus infection, OR odds ratio, CI confidence interval, BMI body mass index, HCV hepatitis C virus, RNA ribonucleic acid, ALT alanine transaminase, eGFR estimated glomerular filtration rate, TG triglycerides, TC total cholesterol, HOMA-IR homeostatic model assessment for insulin resistance, Fe/TIBC serum Iron/total iron binding capacity, Hb hemoglobin, NLR neutrophil lymphocyte ratio, FIB-4 fibrosis-4, IFNL3 interferon-λ3.